Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,952 public trials 630 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Active, Not Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • UC Irvine Medical Center Orange, California, United States
  • Sibley Memorial Hospital Washington D.C., District of Columbia, United States
  • Emory University Atlanta, Georgia, United States
View all 44 locations
View Trial Details
Active, Not Recruiting

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Goodyear, Arizona, United States
  • Research Site Fort Myers, Florida, United States
  • Research Site St. Petersburg, Florida, United States
View all 44 locations
View Trial Details
Active, Not Recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Arizona Urology Specialists Tucson, Arizona, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Genesis Research San Diego, California, United States
  • Wichita Urology Group Wichita, Kansas, United States
View all 65 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • The Second Hospital and Clinical Medical School, Lanzhou University Lanzhou, Gansu, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 18 locations
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • The University of Alabama at Birmingham ( Site 0010) Birmingham, Alabama, United States
  • UC San Diego ( Site 0050) La Jolla, California, United States
  • Cedars Sinai Medical Center ( Site 0027) Los Angeles, California, United States
  • University of California Irvine ( Site 0029) Orange, California, United States
View all 262 locations
View Trial Details

Related conditions